Lytix Biopharma ASA - New share capital registered

Oslo, Norway, 25 November 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("**Lytix**" or the "**Company**") on 18 November 2026 regarding the successful placement of new shares through a private placement (the "**Private Placement**") and a retail offering in Norway (the "**Retail Offering**").

The share capital increase relating to the Private Placement and the Retail Offering has been registered today with the Norwegian Register of Business Enterprises. In total, 10,000,000 shares (the "**New Shares**") have been issued through the Private Placement. The Company's new share capital is NOK 8,690,000.50, divided into 86,900,005 shares, each with a par value of NOK 0.10.

The New Shares are expected to be registered in the Norwegian Central Securities Depository (VPS) either today, or tomorrow, 26 November 2026.

Disclosure regulation:

This information is subject to a duty of disclosure pursuant to the Company's continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:

Gjest Breistein, CFO

+47 952 60 512

gjest.breistein@lytixbiopharma.com

About Lytix Biopharma

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to effectively prime durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker LYTIX. Ruxotemitide315!